1. Home
  2. VOD vs RMD Comparison

VOD vs RMD Comparison

Compare VOD & RMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Vodafone Group Plc

VOD

Vodafone Group Plc

N/A

Current Price

$14.48

Market Cap

34.4B

ML Signal

N/A

Logo ResMed Inc.

RMD

ResMed Inc.

N/A

Current Price

$252.65

Market Cap

36.8B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
VOD
RMD
Founded
1984
1989
Country
United Kingdom
United States
Employees
86702
N/A
Industry
Telecommunications Equipment
Medical/Dental Instruments
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
34.4B
36.8B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
VOD
RMD
Price
$14.48
$252.65
Analyst Decision
Sell
Buy
Analyst Count
3
11
Target Price
N/A
$293.70
AVG Volume (30 Days)
3.8M
979.8K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
3.42%
0.95%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$11.65
$10.64
Revenue Next Year
$5.40
$7.38
P/E Ratio
N/A
$25.61
Revenue Growth
N/A
N/A
52 Week Low
$8.05
$199.92
52 Week High
$15.91
$293.81

Technical Indicators

Market Signals
Indicator
VOD
RMD
Relative Strength Index (RSI) 40.71 45.81
Support Level $11.23 $250.18
Resistance Level $15.90 $259.24
Average True Range (ATR) 0.25 5.78
MACD -0.20 -0.58
Stochastic Oscillator 16.57 37.51

Price Performance

Historical Comparison
VOD
RMD

About VOD Vodafone Group Plc

Vodafone operates mobile and fixed-line networks and businesses across Europe, Africa, and the Middle East. Its largest market is Germany, where it is the second mobile operator after Deutsche Telekom and owns two cable network after acquiring Kabel Deutschland in 2013 and Liberty Global Germany in 2019. In the UK Vodafone merger with CK Hutchison in 2024, consolidating the mobile market. It also divested its Spanish and Italian divisions in that same year, given their low returns on invested capital.

About RMD ResMed Inc.

ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.

Share on Social Networks: